世界のホルモン不応性乳がん市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Hormone Refractory Breast Cancer Market Size, Status and Forecast 2021-2027

• レポートコード：QFJ1-4319 • 出版社/出版日：QYResearch / 2021年6月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、100ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療

• 販売価格（消費税別）

Single User	￥577,200 (USD3,900)	▷ お問い合わせ
Multi User	￥865,800 (USD5,850)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

QYResearch社発行の本調査レポートでは、ホルモン不応性乳がんの世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（腫瘍マーカー療法、遺伝子発現療法、遺伝子変異療法）、用途別市場規模（科学研究生産、生物科学技術、医療技術、医療機器）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。 ・市場概要 ・ホルモン不応性乳がんの市場動向 ・企業の競争状況、市場シェア ・ホルモン不応性乳がんの種類別市場規模と予測2016-2027（腫瘍マーカー療法、遺伝子発現療法、遺伝子変異療法） ・ホルモン不応性乳がんの用途別市場規模と予測2016-2027（科学研究生産、生物科学技術、医療技術、医療機器） ・ホルモン不応性乳がんの北米市場規模2016-2027（アメリカ、カナダ） ・ホルモン不応性乳がんの欧州市場規模2016-2027（ドイツ、フランス、イギリス等） ・ホルモン不応性乳がんのアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・ホルモン不応性乳がんの中南米市場規模2016-2027（メキシコ、ブラジル） ・ホルモン不応性乳がんの中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（AstraZeneca、AmpliMed Corporation、Roche、Bluefish Pharmaceuticals AB、NeoCorp、Sanofi Genzyme、Neopharm、Boehringer Ingelheim GmbH） ・結論

An increasing number of hormone therapies have made refractory breast cancer resistant to treatment, increased incidence of breast cancer, aging population, increased demand for advanced therapies, increased incidence of hormone-refractory breast cancer and the existence of a large number of anti-cancer pipeline drugs, all of which drive the growth of hormone-refractory breast cancer market.

Market Analysis and Insights: Global Hormone Refractory Breast Cancer Market
The global Hormone Refractory Breast Cancer market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Hormone Refractory Breast Cancer market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Hormone Refractory Breast Cancer market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Hormone Refractory Breast Cancer market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Hormone Refractory Breast Cancer market.

Global Hormone Refractory Breast Cancer Scope and Market Size
Hormone Refractory Breast Cancer market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Hormone Refractory Breast Cancer market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Tumor Markers Therapy
Gene Expression Therapy
Gene Mutation Therapy

Segment by Application
Scientific Research and Production
Biological Science and Technology
Medical Technology
Medical Apparatus and Instruments

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
AstraZeneca
AmpliMed Corporation
Roche
Bluefish Pharmaceuticals AB
NeoCorp
Sanofi Genzyme
Neopharm
Boehringer Ingelheim GmbH

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Hormone Refractory Breast Cancer Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Tumor Markers Therapy
1.2.3 Gene Expression Therapy
1.2.4 Gene Mutation Therapy
1.3 Market by Application
1.3.1 Global Hormone Refractory Breast Cancer Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Scientific Research and Production
1.3.3 Biological Science and Technology
1.3.4 Medical Technology
1.3.5 Medical Apparatus and Instruments
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Hormone Refractory Breast Cancer Market Perspective (2016-2027)
2.2 Hormone Refractory Breast Cancer Growth Trends by Regions
2.2.1 Hormone Refractory Breast Cancer Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Hormone Refractory Breast Cancer Historic Market Share by Regions (2016-2021)
2.2.3 Hormone Refractory Breast Cancer Forecasted Market Size by Regions (2022-2027)
2.3 Hormone Refractory Breast Cancer Industry Dynamic
2.3.1 Hormone Refractory Breast Cancer Market Trends
2.3.2 Hormone Refractory Breast Cancer Market Drivers
2.3.3 Hormone Refractory Breast Cancer Market Challenges
2.3.4 Hormone Refractory Breast Cancer Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Hormone Refractory Breast Cancer Players by Revenue
3.1.1 Global Top Hormone Refractory Breast Cancer Players by Revenue (2016-2021)
3.1.2 Global Hormone Refractory Breast Cancer Revenue Market Share by Players (2016-2021)
3.2 Global Hormone Refractory Breast Cancer Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Hormone Refractory Breast Cancer Revenue
3.4 Global Hormone Refractory Breast Cancer Market Concentration Ratio
3.4.1 Global Hormone Refractory Breast Cancer Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Hormone Refractory Breast Cancer Revenue in 2020
3.5 Hormone Refractory Breast Cancer Key Players Head office and Area Served
3.6 Key Players Hormone Refractory Breast Cancer Product Solution and Service
3.7 Date of Enter into Hormone Refractory Breast Cancer Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Hormone Refractory Breast Cancer Breakdown Data by Type
4.1 Global Hormone Refractory Breast Cancer Historic Market Size by Type (2016-2021)
4.2 Global Hormone Refractory Breast Cancer Forecasted Market Size by Type (2022-2027)

5 Hormone Refractory Breast Cancer Breakdown Data by Application
5.1 Global Hormone Refractory Breast Cancer Historic Market Size by Application (2016-2021)
5.2 Global Hormone Refractory Breast Cancer Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Hormone Refractory Breast Cancer Market Size (2016-2027)
6.2 North America Hormone Refractory Breast Cancer Market Size by Type
6.2.1 North America Hormone Refractory Breast Cancer Market Size by Type (2016-2021)
6.2.2 North America Hormone Refractory Breast Cancer Market Size by Type (2022-2027)
6.2.3 North America Hormone Refractory Breast Cancer Market Size by Type (2016-2027)
6.3 North America Hormone Refractory Breast Cancer Market Size by Application
6.3.1 North America Hormone Refractory Breast Cancer Market Size by Application (2016-2021)
6.3.2 North America Hormone Refractory Breast Cancer Market Size by Application (2022-2027)
6.3.3 North America Hormone Refractory Breast Cancer Market Size by Application (2016-2027)
6.4 North America Hormone Refractory Breast Cancer Market Size by Country
6.4.1 North America Hormone Refractory Breast Cancer Market Size by Country (2016-2021)
6.4.2 North America Hormone Refractory Breast Cancer Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada

7 Europe
7.1 Europe Hormone Refractory Breast Cancer Market Size (2016-2027)
7.2 Europe Hormone Refractory Breast Cancer Market Size by Type
7.2.1 Europe Hormone Refractory Breast Cancer Market Size by Type (2016-2021)
7.2.2 Europe Hormone Refractory Breast Cancer Market Size by Type (2022-2027)
7.2.3 Europe Hormone Refractory Breast Cancer Market Size by Type (2016-2027)
7.3 Europe Hormone Refractory Breast Cancer Market Size by Application
7.3.1 Europe Hormone Refractory Breast Cancer Market Size by Application (2016-2021)
7.3.2 Europe Hormone Refractory Breast Cancer Market Size by Application (2022-2027)
7.3.3 Europe Hormone Refractory Breast Cancer Market Size by Application (2016-2027)
7.4 Europe Hormone Refractory Breast Cancer Market Size by Country
7.4.1 Europe Hormone Refractory Breast Cancer Market Size by Country (2016-2021)
7.4.2 Europe Hormone Refractory Breast Cancer Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Hormone Refractory Breast Cancer Market Size (2016-2027)
8.2 Asia-Pacific Hormone Refractory Breast Cancer Market Size by Type
8.2.1 Asia-Pacific Hormone Refractory Breast Cancer Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Hormone Refractory Breast Cancer Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Hormone Refractory Breast Cancer Market Size by Type (2016-2027)
8.3 Asia-Pacific Hormone Refractory Breast Cancer Market Size by Application
8.3.1 Asia-Pacific Hormone Refractory Breast Cancer Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Hormone Refractory Breast Cancer Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Hormone Refractory Breast Cancer Market Size by Application (2016-2027)
8.4 Asia-Pacific Hormone Refractory Breast Cancer Market Size by Region
8.4.1 Asia-Pacific Hormone Refractory Breast Cancer Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Hormone Refractory Breast Cancer Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Hormone Refractory Breast Cancer Market Size (2016-2027)
9.2 Latin America Hormone Refractory Breast Cancer Market Size by Type
9.2.1 Latin America Hormone Refractory Breast Cancer Market Size by Type (2016-2021)
9.2.2 Latin America Hormone Refractory Breast Cancer Market Size by Type (2022-2027)
9.2.3 Latin America Hormone Refractory Breast Cancer Market Size by Type (2016-2027)
9.3 Latin America Hormone Refractory Breast Cancer Market Size by Application
9.3.1 Latin America Hormone Refractory Breast Cancer Market Size by Application (2016-2021)
9.3.2 Latin America Hormone Refractory Breast Cancer Market Size by Application (2022-2027)
9.3.3 Latin America Hormone Refractory Breast Cancer Market Size by Application (2016-2027)
9.4 Latin America Hormone Refractory Breast Cancer Market Size by Country
9.4.1 Latin America Hormone Refractory Breast Cancer Market Size by Country (2016-2021)
9.4.2 Latin America Hormone Refractory Breast Cancer Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Hormone Refractory Breast Cancer Market Size (2016-2027)
10.2 Middle East & Africa Hormone Refractory Breast Cancer Market Size by Type
10.2.1 Middle East & Africa Hormone Refractory Breast Cancer Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Hormone Refractory Breast Cancer Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Hormone Refractory Breast Cancer Market Size by Type (2016-2027)
10.3 Middle East & Africa Hormone Refractory Breast Cancer Market Size by Application
10.3.1 Middle East & Africa Hormone Refractory Breast Cancer Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Hormone Refractory Breast Cancer Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Hormone Refractory Breast Cancer Market Size by Application (2016-2027)
10.4 Middle East & Africa Hormone Refractory Breast Cancer Market Size by Country
10.4.1 Middle East & Africa Hormone Refractory Breast Cancer Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Hormone Refractory Breast Cancer Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 AstraZeneca
11.1.1 AstraZeneca Company Details
11.1.2 AstraZeneca Business Overview
11.1.3 AstraZeneca Hormone Refractory Breast Cancer Introduction
11.1.4 AstraZeneca Revenue in Hormone Refractory Breast Cancer Business (2016-2021)
11.1.5 AstraZeneca Recent Development
11.2 AmpliMed Corporation
11.2.1 AmpliMed Corporation Company Details
11.2.2 AmpliMed Corporation Business Overview
11.2.3 AmpliMed Corporation Hormone Refractory Breast Cancer Introduction
11.2.4 AmpliMed Corporation Revenue in Hormone Refractory Breast Cancer Business (2016-2021)
11.2.5 AmpliMed Corporation Recent Development
11.3 Roche
11.3.1 Roche Company Details
11.3.2 Roche Business Overview
11.3.3 Roche Hormone Refractory Breast Cancer Introduction
11.3.4 Roche Revenue in Hormone Refractory Breast Cancer Business (2016-2021)
11.3.5 Roche Recent Development
11.4 Bluefish Pharmaceuticals AB
11.4.1 Bluefish Pharmaceuticals AB Company Details
11.4.2 Bluefish Pharmaceuticals AB Business Overview
11.4.3 Bluefish Pharmaceuticals AB Hormone Refractory Breast Cancer Introduction
11.4.4 Bluefish Pharmaceuticals AB Revenue in Hormone Refractory Breast Cancer Business (2016-2021)
11.4.5 Bluefish Pharmaceuticals AB Recent Development
11.5 NeoCorp
11.5.1 NeoCorp Company Details
11.5.2 NeoCorp Business Overview
11.5.3 NeoCorp Hormone Refractory Breast Cancer Introduction
11.5.4 NeoCorp Revenue in Hormone Refractory Breast Cancer Business (2016-2021)
11.5.5 NeoCorp Recent Development
11.6 Sanofi Genzyme
11.6.1 Sanofi Genzyme Company Details
11.6.2 Sanofi Genzyme Business Overview
11.6.3 Sanofi Genzyme Hormone Refractory Breast Cancer Introduction
11.6.4 Sanofi Genzyme Revenue in Hormone Refractory Breast Cancer Business (2016-2021)
11.6.5 Sanofi Genzyme Recent Development
11.7 Neopharm
11.7.1 Neopharm Company Details
11.7.2 Neopharm Business Overview
11.7.3 Neopharm Hormone Refractory Breast Cancer Introduction
11.7.4 Neopharm Revenue in Hormone Refractory Breast Cancer Business (2016-2021)
11.7.5 Neopharm Recent Development
11.8 Boehringer Ingelheim GmbH
11.8.1 Boehringer Ingelheim GmbH Company Details
11.8.2 Boehringer Ingelheim GmbH Business Overview
11.8.3 Boehringer Ingelheim GmbH Hormone Refractory Breast Cancer Introduction
11.8.4 Boehringer Ingelheim GmbH Revenue in Hormone Refractory Breast Cancer Business (2016-2021)
11.8.5 Boehringer Ingelheim GmbH Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Hormone Refractory Breast Cancer Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Tumor Markers Therapy
Table 3. Key Players of Gene Expression Therapy
Table 4. Key Players of Gene Mutation Therapy
Table 5. Global Hormone Refractory Breast Cancer Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global Hormone Refractory Breast Cancer Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Hormone Refractory Breast Cancer Market Size by Regions (2016-2021) & (US$ Million)
Table 8. Global Hormone Refractory Breast Cancer Market Share by Regions (2016-2021)
Table 9. Global Hormone Refractory Breast Cancer Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 10. Global Hormone Refractory Breast Cancer Market Share by Regions (2022-2027)
Table 11. Hormone Refractory Breast Cancer Market Trends
Table 12. Hormone Refractory Breast Cancer Market Drivers
Table 13. Hormone Refractory Breast Cancer Market Challenges
Table 14. Hormone Refractory Breast Cancer Market Restraints
Table 15. Global Hormone Refractory Breast Cancer Revenue by Players (2016-2021) & (US$ Million)
Table 16. Global Hormone Refractory Breast Cancer Market Share by Players (2016-2021)
Table 17. Global Top Hormone Refractory Breast Cancer Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Hormone Refractory Breast Cancer as of 2020)
Table 18. Ranking of Global Top Hormone Refractory Breast Cancer Companies by Revenue (US$ Million) in 2020
Table 19. Global 5 Largest Players Market Share by Hormone Refractory Breast Cancer Revenue (CR5 and HHI) & (2016-2021)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Hormone Refractory Breast Cancer Product Solution and Service
Table 22. Date of Enter into Hormone Refractory Breast Cancer Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Hormone Refractory Breast Cancer Market Size by Type (2016-2021) (US$ Million)
Table 25. Global Hormone Refractory Breast Cancer Revenue Market Share by Type (2016-2021)
Table 26. Global Hormone Refractory Breast Cancer Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 27. Global Hormone Refractory Breast Cancer Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 28. Global Hormone Refractory Breast Cancer Market Size Share by Application (2016-2021) & (US$ Million)
Table 29. Global Hormone Refractory Breast Cancer Revenue Market Share by Application (2016-2021)
Table 30. Global Hormone Refractory Breast Cancer Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 31. Global Hormone Refractory Breast Cancer Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 32. North America Hormone Refractory Breast Cancer Market Size by Type (2016-2021) (US$ Million)
Table 33. North America Hormone Refractory Breast Cancer Market Size by Type (2022-2027) & (US$ Million)
Table 34. North America Hormone Refractory Breast Cancer Market Size by Application (2016-2021) (US$ Million)
Table 35. North America Hormone Refractory Breast Cancer Market Size by Application (2022-2027) & (US$ Million)
Table 36. North America Hormone Refractory Breast Cancer Market Size by Country (2016-2021) & (US$ Million)
Table 37. North America Hormone Refractory Breast Cancer Market Size by Country (2022-2027) & (US$ Million)
Table 38. Europe Hormone Refractory Breast Cancer Market Size by Type (2016-2021) (US$ Million)
Table 39. Europe Hormone Refractory Breast Cancer Market Size by Type (2022-2027) & (US$ Million)
Table 40. Europe Hormone Refractory Breast Cancer Market Size by Application (2016-2021) (US$ Million)
Table 41. Europe Hormone Refractory Breast Cancer Market Size by Application (2022-2027) & (US$ Million)
Table 42. Europe Hormone Refractory Breast Cancer Market Size by Country (2016-2021) & (US$ Million)
Table 43. Europe Hormone Refractory Breast Cancer Market Size by Country (2022-2027) & (US$ Million)
Table 44. Asia-Pacific Hormone Refractory Breast Cancer Market Size by Type (2016-2021) (US$ Million)
Table 45. Asia-Pacific Hormone Refractory Breast Cancer Market Size by Type (2022-2027) & (US$ Million)
Table 46. Asia-Pacific Hormone Refractory Breast Cancer Market Size by Application (2016-2021) (US$ Million)
Table 47. Asia-Pacific Hormone Refractory Breast Cancer Market Size by Application (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Hormone Refractory Breast Cancer Market Size by Region (2016-2021) & (US$ Million)
Table 49. Asia-Pacific Hormone Refractory Breast Cancer Market Size by Region (2022-2027) & (US$ Million)
Table 50. Latin America Hormone Refractory Breast Cancer Market Size by Type (2016-2021) (US$ Million)
Table 51. Latin America Hormone Refractory Breast Cancer Market Size by Type (2022-2027) & (US$ Million)
Table 52. Latin America Hormone Refractory Breast Cancer Market Size by Application (2016-2021) (US$ Million)
Table 53. Latin America Hormone Refractory Breast Cancer Market Size by Application (2022-2027) & (US$ Million)
Table 54. Latin America Hormone Refractory Breast Cancer Market Size by Country (2016-2021) & (US$ Million)
Table 55. Latin America Hormone Refractory Breast Cancer Market Size by Country (2022-2027) & (US$ Million)
Table 56. Middle East & Africa Hormone Refractory Breast Cancer Market Size by Type (2016-2021) (US$ Million)
Table 57. Middle East & Africa Hormone Refractory Breast Cancer Market Size by Type (2022-2027) & (US$ Million)
Table 58. Middle East & Africa Hormone Refractory Breast Cancer Market Size by Application (2016-2021) (US$ Million)
Table 59. Middle East & Africa Hormone Refractory Breast Cancer Market Size by Application (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Hormone Refractory Breast Cancer Market Size by Country (2016-2021) & (US$ Million)
Table 61. Middle East & Africa Hormone Refractory Breast Cancer Market Size by Country (2022-2027) & (US$ Million)
Table 62. AstraZeneca Company Details
Table 63. AstraZeneca Business Overview
Table 64. AstraZeneca Hormone Refractory Breast Cancer Product
Table 65. AstraZeneca Revenue in Hormone Refractory Breast Cancer Business (2016-2021) & (US$ Million)
Table 66. AstraZeneca Recent Development
Table 67. AmpliMed Corporation Company Details
Table 68. AmpliMed Corporation Business Overview
Table 69. AmpliMed Corporation Hormone Refractory Breast Cancer Product
Table 70. AmpliMed Corporation Revenue in Hormone Refractory Breast Cancer Business (2016-2021) & (US$ Million)
Table 71. AmpliMed Corporation Recent Development
Table 72. Roche Company Details
Table 73. Roche Business Overview
Table 74. Roche Hormone Refractory Breast Cancer Product
Table 75. Roche Revenue in Hormone Refractory Breast Cancer Business (2016-2021) & (US$ Million)
Table 76. Roche Recent Development
Table 77. Bluefish Pharmaceuticals AB Company Details
Table 78. Bluefish Pharmaceuticals AB Business Overview
Table 79. Bluefish Pharmaceuticals AB Hormone Refractory Breast Cancer Product
Table 80. Bluefish Pharmaceuticals AB Revenue in Hormone Refractory Breast Cancer Business (2016-2021) & (US$ Million)
Table 81. Bluefish Pharmaceuticals AB Recent Development
Table 82. NeoCorp Company Details
Table 83. NeoCorp Business Overview
Table 84. NeoCorp Hormone Refractory Breast Cancer Product
Table 85. NeoCorp Revenue in Hormone Refractory Breast Cancer Business (2016-2021) & (US$ Million)
Table 86. NeoCorp Recent Development
Table 87. Sanofi Genzyme Company Details
Table 88. Sanofi Genzyme Business Overview
Table 89. Sanofi Genzyme Hormone Refractory Breast Cancer Product
Table 90. Sanofi Genzyme Revenue in Hormone Refractory Breast Cancer Business (2016-2021) & (US$ Million)
Table 91. Sanofi Genzyme Recent Development
Table 92. Neopharm Company Details
Table 93. Neopharm Business Overview
Table 94. Neopharm Hormone Refractory Breast Cancer Product
Table 95. Neopharm Revenue in Hormone Refractory Breast Cancer Business (2016-2021) & (US$ Million)
Table 96. Neopharm Recent Development
Table 97. Boehringer Ingelheim GmbH Company Details
Table 98. Boehringer Ingelheim GmbH Business Overview
Table 99. Boehringer Ingelheim GmbH Revenue in Hormone Refractory Breast Cancer Business (2016-2021) & (US$ Million)
Table 100. Boehringer Ingelheim GmbH Recent Development
Table 101. Research Programs/Design for This Report
Table 102. Key Data Information from Secondary Sources
Table 103. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Hormone Refractory Breast Cancer Market Share by Type: 2020 VS 2027
Figure 2. Tumor Markers Therapy Features
Figure 3. Gene Expression Therapy Features
Figure 4. Gene Mutation Therapy Features
Figure 5. Global Hormone Refractory Breast Cancer Market Share by Application: 2020 VS 2027
Figure 6. Scientific Research and Production Case Studies
Figure 7. Biological Science and Technology Case Studies
Figure 8. Medical Technology Case Studies
Figure 9. Medical Apparatus and Instruments Case Studies
Figure 10. Hormone Refractory Breast Cancer Report Years Considered
Figure 11. Global Hormone Refractory Breast Cancer Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 12. Global Hormone Refractory Breast Cancer Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 13. Global Hormone Refractory Breast Cancer Market Share by Regions: 2020 VS 2027
Figure 14. Global Hormone Refractory Breast Cancer Market Share by Regions (2022-2027)
Figure 15. Global Hormone Refractory Breast Cancer Market Share by Players in 2020
Figure 16. Global Top Hormone Refractory Breast Cancer Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Hormone Refractory Breast Cancer as of 2020
Figure 17. The Top 10 and 5 Players Market Share by Hormone Refractory Breast Cancer Revenue in 2020
Figure 18. Global Hormone Refractory Breast Cancer Revenue Market Share by Type (2016-2021)
Figure 19. Global Hormone Refractory Breast Cancer Revenue Market Share by Type (2022-2027)
Figure 20. North America Hormone Refractory Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 21. North America Hormone Refractory Breast Cancer Market Share by Type (2016-2027)
Figure 22. North America Hormone Refractory Breast Cancer Market Share by Application (2016-2027)
Figure 23. North America Hormone Refractory Breast Cancer Market Share by Country (2016-2027)
Figure 24. United States Hormone Refractory Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Canada Hormone Refractory Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Europe Hormone Refractory Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Europe Hormone Refractory Breast Cancer Market Share by Type (2016-2027)
Figure 28. Europe Hormone Refractory Breast Cancer Market Share by Application (2016-2027)
Figure 29. Europe Hormone Refractory Breast Cancer Market Share by Country (2016-2027)
Figure 30. Germany Hormone Refractory Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. France Hormone Refractory Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. U.K. Hormone Refractory Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Italy Hormone Refractory Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Russia Hormone Refractory Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Nordic Hormone Refractory Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Asia-Pacific Hormone Refractory Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Asia-Pacific Hormone Refractory Breast Cancer Market Share by Type (2016-2027)
Figure 38. Asia-Pacific Hormone Refractory Breast Cancer Market Share by Application (2016-2027)
Figure 39. Asia-Pacific Hormone Refractory Breast Cancer Market Share by Region (2016-2027)
Figure 40. China Hormone Refractory Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. Japan Hormone Refractory Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. South Korea Hormone Refractory Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Southeast Asia Hormone Refractory Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. India Hormone Refractory Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Australia Hormone Refractory Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Latin America Hormone Refractory Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Latin America Hormone Refractory Breast Cancer Market Share by Type (2016-2027)
Figure 48. Latin America Hormone Refractory Breast Cancer Market Share by Application (2016-2027)
Figure 49. Latin America Hormone Refractory Breast Cancer Market Share by Country (2016-2027)
Figure 50. Mexico Hormone Refractory Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Brazil Hormone Refractory Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Middle East & Africa Hormone Refractory Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Middle East & Africa Hormone Refractory Breast Cancer Market Share by Type (2016-2027)
Figure 54. Middle East & Africa Hormone Refractory Breast Cancer Market Share by Application (2016-2027)
Figure 55. Middle East & Africa Hormone Refractory Breast Cancer Market Share by Country (2016-2027)
Figure 56. Turkey Hormone Refractory Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. Saudi Arabia Hormone Refractory Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. UAE Hormone Refractory Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. AstraZeneca Revenue Growth Rate in Hormone Refractory Breast Cancer Business (2016-2021)
Figure 60. AmpliMed Corporation Revenue Growth Rate in Hormone Refractory Breast Cancer Business (2016-2021)
Figure 61. Roche Revenue Growth Rate in Hormone Refractory Breast Cancer Business (2016-2021)
Figure 62. Bluefish Pharmaceuticals AB Revenue Growth Rate in Hormone Refractory Breast Cancer Business (2016-2021)
Figure 63. NeoCorp Revenue Growth Rate in Hormone Refractory Breast Cancer Business (2016-2021)
Figure 64. Sanofi Genzyme Revenue Growth Rate in Hormone Refractory Breast Cancer Business (2016-2021)
Figure 65. Neopharm Revenue Growth Rate in Hormone Refractory Breast Cancer Business (2016-2021)
Figure 66. Boehringer Ingelheim GmbH Revenue Growth Rate in Hormone Refractory Breast Cancer Business (2016-2021)
Figure 67. Bottom-up and Top-down Approaches for This Report
Figure 68. Data Triangulation
Figure 69. Key Executives Interviewed

---